Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a report released on Sunday morning,Wall Street Zen reports.

A number of other equities analysts have also weighed in on the company. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, July 8th. Chardan Capital initiated coverage on Tvardi Therapeutics in a research note on Tuesday, October 20th. They set a “buy” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, October 2nd. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a report on Wednesday, July 8th. Finally, Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.40.

Tvardi Therapeutics Stock Performance

TVRD opened at $0.83 on Friday. The firm’s fifty day moving average is $1.34 and its 200 day moving average is $2.73. Tvardi Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $5.69.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Equities analysts forecast that Tvardi Therapeutics will post -2.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Tvardi Therapeutics in the second quarter worth about $181,000. Susquehanna International Group LLP bought a new position in Tvardi Therapeutics during the second quarter valued at approximately $63,000. Finally, GSA Capital Partners LLP purchased a new position in Tvardi Therapeutics during the 2nd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.